Table 3.

Adverse Events and Laboratory Abnormalities During Treatment Period

	Sofosbuvir + Ledipasvir for 12 weeks (n=20)	Sofosbuvir + Ledipasvir + GS-9669 for 6 weeks (n=20)	Sofosbuvir + Ledipasvir + GS-9451 for 6 weeks (n=20)
Any adverse event during treatment –n(%)	20 (100)	20 (100)	20 (100)
Any serious adverse event during treatment - n(%)	0	0	2(10)
Common adverse events** - n(%)
Night sweats	0	2 (10)	0
Constipation	0	2 (10)	1 (5)
Vomiting	1 (5)	2 (10)	0
Nausea	1 (5)	2 (10)	1 (5)
Shoulder pain	2 (10)	0	0
Common cold	4 (20)	1 (5)	1 (5)
Fatigue	2 (10)	2 (10)	4 (20)
Diarrhea	1 (5)	5 (25)	3 (15)
Headache	5 (25)	5 (25)	0
Rash	3 (15)	1 (5)	0
Abdominal pain	2 (10)	2 (10)	0
Back Pain	2 (10)	0	1 (5)
Laboratory abnormalities
Any Grade 3 abnormality during treatment - n (%)	4 (20)	2 (10)	4 (20)
Hypophosphatemia
Grade 3	0	2 (10)	0
Elevated serum creatinine
Grade 3	0	0	3 (15)
Decreased hemoglobin
Grade 3	0	0	1 (5)
Elevated ALT
Grade 3	1 (5)	0	0
Elevated AST
Grade 3	1 (5)	0	0
Elevated LDL
Grade 3	1 (5)	0	0
Hyperglycemia
Grade 3	1 (5)	0	0
Hypoglycemia
Grade 3	1 (5)	0	0

^*Treatment period includes time on study medication and 30 days after discontinuation

^**Occurring in ≥10% of patients